PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
The Basel-based pharmaceutical company Roche has entered into a research collaboration with the U.S. company MacroGenics to develop novel bispecific molecules for use in the treatment of cancer and other diseases.
Roche and MacroGenics intend to develop bispecific molecules that can be used in the treatment of several diseases. According to a statement announcing the partnership, both companies will bring their respective technology platforms to the collaboration. Roche has the option to further develop and commercialize any product candidate stemming from the collaboration.
MacroGenics focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases. Bispecific molecules consist of two monoclonal antibodies.
“By combining our two companies’ respective scientific talent, technology platforms and experience, we hope to generate a compelling product candidate to address unmet patient needs,” said Scott Koenig, president and CEO of MacroGenics.
Under the terms of the agreement, Roche will pay MacroGenics an upfront payment of $10 million. MacroGenics will also be eligible to receive up to $370 million in potential milestone payments.